Back to Results
First PageMeta Content
Blindness / Macular degeneration / Vascular endothelial growth factor / Bevacizumab / Ranibizumab / Macular edema / Diabetic retinopathy / Retina / Retinitis pigmentosa / Medicine / Ophthalmology / Health


Microsoft WordResearch update.docx
Add to Reading List

Document Date: 2010-12-15 00:10:36

Open Document

File Size: 1,26 MB

Share Result on Facebook

Company

Macular Degeneration Foundation Ltd / AMD / VisionCare Inc / /

Continent

Europe / /

Country

Germany / United States / Australia / /

Currency

USD / /

Event

FDA Phase / /

Facility

Ear Hospital / National Eye Institute / /

IndustryTerm

treatment for Stargardt’s Disease / imaging / biochemical chain / energy / controlled x-ray device / /

MedicalCondition

particular disease / retinitis pigmentosa / important diseases / Macular Degeneration / injury / different disease / Diabetic retinopathy/macular edema / retinal vein occlusions / blindness / Stargardt’s Disease / chronic inflammatory response / disease / Cure Blindness / total blindness / diabetes / diseases / diabetic macular edema / Retinal vein occlusion / inflammation / highly complex disease / cataract / Because Macular Degeneration / /

MedicalTreatment

radiation therapy / gene therapy / Radiation treatment / brachytherapy / cataract surgery / /

Organization

National Eye Institute / Victorian Eye and Ear Hospital in Melbourne / Therapeutic Goods Administration / Food & Drug Administration / Macular Degeneration Foundation / FDA / European Union / /

Person

Ray Another / /

/

Product

alprostadil / Avastin / Lucentis / Vitamin A / this / ACU4429 / US / /

ProvinceOrState

Maryland / /

Technology

Radiation / x-ray / transplantation / stem cells / gene therapy / Laser / drug development / /

URL

www.mdfoundation.com.au / /

SocialTag